

1 **Quantitative analysis of chest computed tomography of COVID-19 pneumonia using a software**  
2 **widely used in Japan**

3

4 Minako Suzuki<sup>1\*</sup>, Yoshimi Fujii<sup>2¶</sup>, Yurie Nishimura<sup>2¶</sup>, Kazuma Yasui<sup>2¶</sup>, Hidefumi Fujisawa<sup>1¶</sup>

5

6 <sup>1</sup> Department of Radiology, Showa University Northern Yokohama Hospital, Yokohama, Kanagawa,

7 Japan

8 <sup>2</sup> Department of Radiology, Fujisawa City Hospital, Fujisawa, Kanagawa, Japan

9

10 \* Corresponding author:

11 E-mail: [minacom69@gmail.com](mailto:minacom69@gmail.com) (MS)

12

13 **Short title:** Quantitative analysis of chest CT of COVID-19 pneumonia

14

15 <sup>¶</sup>These authors contributed equally to this work.

16

## 17 Abstract

18 This study aimed to determine the optimal conditions to measure the percentage of area  
 19 considered as pneumonia (pneumonia volume ratio, PVR) and the computed tomography  
 20 (CT) score due to coronavirus disease 2019 (COVID-19) using the Ziostation2 image  
 21 analysis software (Z2; Ziosoft, Tokyo, Japan), which is popular in Japan, and to evaluate its  
 22 usefulness in assessing the clinical severity. We included 53 patients (41 men and 12 women,  
 23 mean age: 61.3 years) diagnosed with COVID-19 using the polymerase chain reaction who  
 24 had undergone chest CT and were hospitalized between January 2020 and January 2021.  
 25 Based on the COVID-19 infection severity, the patients were classified as mild (n=38) or  
 26 severe (n=15). For 10 randomly selected samples, the PVR and CT scores by Z2 under  
 27 different conditions and the visual simple PVR and CT scores were compared, and the  
 28 conditions with the highest statistical agreement were determined. The usefulness of the  
 29 clinical severity assessment based on PVR and CT scores using Z2 under the determined  
 30 conditions was statistically evaluated. The best agreement with the visual measurement was  
 31 achieved by the Z2 measurement condition of  $\geq -600$  HU. The areas under the receiver  
 32 operating characteristic curves, the Youden index, and the sensitivity, specificity, and p-values  
 33 of PVR and CT scores by Z2 were as follows: PVR; 0.881, 18.69, 66.7, 94.7, and <0.001, CT  
 34 score; 0.77, 7.5, 40, 74, and 0.002, respectively. We determined the optimal condition for  
 35 assessing the PVR of COVID-19 pneumonia using Z2 and demonstrated that the AUC of  
 36 PVR was higher than that of the CT score in the assessment of clinical severity. The  
 37 introduction of new technologies is time-consuming and expensive; our method has high  
 38 clinical utility and can be promptly used in any facility where Z2 has been introduced.

## 40 Introduction

41 The coronavirus disease 2019 (COVID-19) pandemic caused by the novel coronavirus severe  
 42 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in Wuhan,  
 43 China, and reported in December 2019 [1]. The pandemic prevails with an increasing number  
 44 of infections and deaths. In Japan, the first COVID-19 case was reported in January 2020 [2],  
 45 and by April 2023, over 33 million people had been infected, and more than 74000 people  
 46 had died [3]. After the Omicron strain of SARS-CoV-2 became prevalent, the number of  
 47 severe cases complicated by pneumonia decreased, and the vaccination had spread socially.  
 48 In May 2023, the legal classification was changed, and it was decided that a COVID-19  
 49 infection would be treated on the same level as an influenza virus infection [3].

50 This study was conducted with the aim of determining how the radiology department  
 51 of a city hospital in Japan could use existing image analysis software to contribute to clinical  
 52 practice at a time when the pre-Delta strain COVID-19 virus was predominant.

53 During the study period, COVID-19 infection had a high complication rate with  
 54 pneumonia, especially in older adults [4, 5], with a high rate of aggravation and mortality,  
 55 and it became necessary to distribute limited medical resources. The discrimination between  
 56 mild and severe cases at the emergency department was an important and burdensome task.  
 57 Typically, the severity was determined by symptoms, age, complications, blood tests, and  
 58 computed tomography (CT) findings. The CT findings were generally evaluated visually, and  
 59 the CT scores based on visual evaluation were not accurate or objective and took time and  
 60 effort on the part of the evaluator. There are many reports on the CT severity assessment of  
 61 COVID-19-associated pneumonia using an imaging software. The measurement methods and  
 62 evaluation conditions differ for each individual tool, and few of them have been widely  
 63 adopted in clinical settings.

64 The Ziostation2 image analysis software (Z2; Ziosoft, Tokyo, Japan) had been  
 65 introduced in approximately 300 facilities in Japan, which was designed to quantify

66 pulmonary emphysema in patients with chronic obstructive pulmonary disease. When a  
67 region above a certain concentration is recognized as a pneumonia region, the pneumonia  
68 volume ratio (PVR) can be measured by changing the threshold setting of the CT value (Fig  
69 1a, b). To the best of our knowledge, there are no reports of COVID-19 pneumonia  
70 assessment by Z2.

71

72 **Fig 1. Images displayed on the console of the Z2.** Z2 monitor screen. The PVR above a  
73 certain concentration is displayed in the upper right corner (red square). LAV, low attenuation  
74 volume; LL, left lower lobe; LU, left upper lobe; nLAV, not LAV (lung volume other than  
75 LAV); PVR, pneumonia volume ratio; RL, right lower lobe; RM, right middle lobe; RU, right  
76 upper lobe; Z2, Ziostation2.

77

78 Since Z2 has not been set to evaluate pneumonia, it is necessary to determine the  
79 threshold in Hounsfield units (HUs) for it. Therefore, it was decided to set the threshold at the  
80 concentration that most closely matched the visual evaluation.

81 In this study, we determined the appropriate conditions for the evaluation of  
82 COVID-19 pneumonia by Z2 through comparison with visual evaluation results and  
83 examined the usefulness of the clinical severity assessment of Z2.

84

## 85 **Materials and Methods**

### 86 **Study population**

87 This study adhered to the principles of the Declaration of Helsinki and was approved by the  
88 Ethical Review Committee of Fujisawa City Hospital (approval number: F2021022). The

study was conducted retrospectively using imaging data and electronic medical records. An informed consent was provided by all patients in an opt-out manner on the website.

We evaluated patients diagnosed with COVID-19 using a polymerase chain reaction test who required a chest CT scan at our hospital and inpatient hospital care between January 2020 and January 2021. The patients who had an initial CT scan at another hospital or those who were initially treated at another hospital and subsequently transferred to our hospital, and cases without pneumonia findings on chest CT were excluded. Ten samples were randomly selected from patients under 65 years of age and with an uncomplicated condition.

The clinical severity of COVID-19 was classified as mild ( $\text{SpO}_2 > 93\%$ ) or severe ( $\text{SpO}_2 \leq 93\%$ , intubation, and intensive care unit management) based on the symptoms at the time of hospitalization, according to the guidelines of the Ministry of Health and Welfare [4]. The clinical severity, symptoms, comorbidities, blood test values, and clinical course were retrieved from the electronic medical records.

## CT protocol

The chest CT scans were obtained using 64-multidetector CT scanners (SOMATOM Definition AS 64; Siemens Healthineers, Erlangen, Germany). The CT parameters used at our hospital were as follows: 120 kVp, 160-316 mA current intelligent control (auto mA), and 5 mm slice thickness reconstruction. All CT examinations were performed without the use of intravenous contrast agents. The EV Report picture archiving and communication system (PACS) (PSP Corporation, Tokyo, Japan) was used to evaluate the CT findings.

## CT image analysis

Two radiologists evaluated the CT findings of pneumonia in all patients (Y.N. and M.S.) in consultation for the presence or absence of ground-glass opacity (GGO) (−/+), crazy-paving finding (−/+), consolidation (none/mild/moderate/severe), and emphysema (−/+).

For the 10 selected participants, visual evaluation of the PVR was performed independently by two radiologists (Y.F. and M.S.) using the free-form curve drawing tool of the PACS by adding up the area of the lungs and the pneumonia area freehand at 1.5-cm intervals in the coronal chest CT images (Fig 2). In the same participants, the two radiologists independently scored the percentage of pneumonia area in each lobe using visual measurements (0: 0%, 1: 25%, 2: 25–50%, 3: 50–75%, and 4: 75–100%).

**Fig 2. Visual measurement of PVR.** Two radiologists independently selected the entire lung field and pneumonia area every 1.5 cm on the coronal view using a drawing tool on the PACS (PSP Corporation, Tokyo, Japan), and added these up to measure the PVR. The blue line indicates the entire lung field (mm<sup>2</sup>), and the yellow line indicates the pneumonia area (mm<sup>2</sup>). The minimum and maximum in the figure represent CT values in the region. PACS, report picture archiving and communication system; PVR, pneumonia volume ratio; min, minimum; max, maximum; SD, standard deviation.

Z2 provided the quantification of the emphysema, healthy lung parenchyma, GGO, and consolidation based on a HU. Z2 can divide segments and calculate total volumes for both the right and left lungs. In the measurement of PVR and CT scores in the 10 selected participants using Z2, the lung fields above a particular concentration were set as pneumonia areas and measured at  $\geq -500$  HU,  $\geq -550$  HU,  $\geq -600$  HU,  $\geq -650$  HU, and  $\geq -700$  HU. Z2 may not recognize the subpleural consolidation area as a lung field, and the total lung volume

may be underestimated (Fig 3); therefore, radiologist A (M.S.) made the appropriate corrections manually.

**Fig 3. Dorsal subpleural consolidations are not recognized as part of the lung and require manual correction.** The white arrows indicate the areas that needed to be manually corrected.

## Statistical analysis

The presence of significant differences in participant background (age, sex, number of days from disease onset to CT evaluation, and laboratory test results) between the mild and severe groups was evaluated using the t-test and chi-square test. The accuracy between the gross measurements of PVR and CT scores by two independent radiologists and the measurements by Z2 were evaluated using the Spearman's rank correlation coefficient. The influence of possible confounding factors of participant background (age, sex, number of days from disease onset to CT evaluation, and presence of comorbidities) on the severity classification of PVR by Z2 was evaluated using the bivariable logistic regression. The usefulness of PVR and CT scores by Z2 under the determined conditions, primary laboratory tests, and CT findings in the clinical severity assessment was determined by the receiver operating characteristic (ROC) curves, Youden index, sensitivity, specificity, and p-values. All statistical analyses were performed using the SPSS software (version 27; IBM, Armonk, NY, USA).

## Results

The number of patients diagnosed with COVID-19 using a polymerase chain reaction test who required a chest CT scan at our hospital and inpatient hospital care between January 2020 and January 2021 were 91. Of these, three patients who received initial treatment at another hospital and 28 patients who had no findings of pneumonia on chest CT were excluded. Two cases were excluded from the study because the thin slice data necessary for Z2 measurement were not saved, and five cases could not be measured by Z2 for unknown reasons.

**Fig 4. The flow chart shows the process of determining the number of study cases to 53.**

In total, 53 participants (41 men and 12 women, with a median age of 61.3 years; 38 in the mild group and 15 in the severe group) were included. Table 1 shows the participants' demographics (age, sex, and presence of comorbidities), laboratory findings, and CT findings. Fifty-two participants presented with COVID-19 symptoms; however, there was no significant difference in the severity of the symptoms between the mild and severe disease groups. Significant differences in the number of days from disease onset to CT evaluation and the presence of comorbidities were found between the two groups. In addition, laboratory results revealed that C-reactive protein (CRP) and lactate dehydrogenase (LDH) levels differed significantly between the two groups. The CT findings showed a significant difference in consolidation between the two groups.

**Table 1. Patient background, blood test, and CT findings**

Factor	Total (n = 53)	Mild (n = 38)	Severe (n = 15)	p-value
--------	----------------	---------------	-----------------	---------



Age (years; median)	61.28 (66)	58.95 (59.5)	67.2 (67.00)	0.148
Sex (male; %)	41 (77.4)	27 (71.1)	14 (93.3)	0.081
Date from onset to CT (range)	6.0 (1–14)	5.2 (1–12)	7.9 (4–14)	0.016
Comorbidities <sup>a</sup> (%)	18 (34.0)	9 (23.7)	9 (60.0)	0.012
DM (%)	6 (11.3)	3 (7.9)	3 (20.0)	0.21
COPD (%)	5 (9.4)	2 (5.3)	3 (20.0)	0.098
CRF (%)	4 (7.5)	3 (7.9)	1 (6.7)	0.879
Obesity (%)	6 (11.3)	1 (2.6)	5 (33.3)	0.0015
Malignancy (%)	3 (5.7)	1 (2.6)	2 (13.3)	0.129
Symptoms (any)	52 (98.1)	37 (97.4)	15 (100)	0.526
Fever (%)	46 (86.8)	33 (86.8)	13 (86.7)	0.986
Cough (%)	22 (41.5)	14 (36.8)	8 (53.3)	0.272
Taste disorder (%)	7 (16.2)	7 (18.4)	0 (0)	0.074
Vomiting or diarrhea (%)	9 (17.0)	8 (21.1)	1 (6.7)	0.21
<hr/>				
Blood tests (range)				
WBC ( $\times 10^9/L$ )	6.6 (2.5–21.7)	6.3 (2.5–21.7)	7.2 (3.5–12.3)	0.33
Lymphocytes (%)	17.8 (4–46.5)	11.6 (4–46.5)	7.5 (5.2–26.4)	0.085
CRP (mg/dL)	8.1 (0.02–29.6)	2.9 (0.02–29.6)	13.1 (2.4–26.0)	0.005
LDH (U/L)	364.8 (144–1136)	302.8 (144–834)	521.8 (233–1136)	< 0.001
AST (U/L)	50.2 (14–160)	46.3 (14–160)	60.1 (25–131)	0.213
ALT (U/L)	43.5 (7–200)	39.97 (7–200)	52.27 (15–163)	0.308
Creatinine (mg/dL)	1.39 (0.31–14.9)	1.15	0.998 (0.52–2.34)	0.455

	(0.31–14.9)			
eGFR (mL/min)	65.8 (30–144)	65.4 (1.6–144)	66.93 (22–100)	0.853
CT findings				
GGO (+) (%)	53 (100)	38 (100)	15 (100)	1
Crazy paving (+) (%)	8 (15.1)	5 (13.2)	3 (20.0)	0.53
Consolidation (–)				
(%)	23 (43.4)	21 (55.3)	2 (13.3)	
(+) (%)	17 (32.1)	12 (31.6)	5 (33.3)	
(++) (%)	8 (15.1)	5 (13.2)	3 (20.0)	
(+++)	5 (9.4)	0 (0)	5 (33.3)	0.0006
Z2 ( $\geq -600$ HU)				
PVR mean (median, range)	12.44 (1.63–63.26)	7.59 (1.63–40.11)	24.71 (3.32–63.26)	< 0.001
CT score mean (median, range)	6.62 (8, 5–15)	5.87 (5, 5–11)	8.53 (7, 5–15)	< 0.001

180

181 CT: computed tomography, DM: diabetes mellitus, COPD: chronic obstructive pulmonary  
182 disease, CRF: chronic renal failure, WBC: white blood cell, CRP: C-reactive protein, LDH:  
183 lactate dehydrogenase, AST: aspartate aminotransferase, ALT: alanine aminotransferase,  
184 eGFR: estimated glomerular filtration rate, GGO: ground-glass opacity, Z2: Ziostation2,  
185 PVR: pneumonia volume ratio

<sup>a</sup>Comorbidities were defined as presence of any of the following: DM, COPD, severe cardiovascular disease, severe CRF, obesity, malignancy under treatment, immunosuppression, and liver cirrhosis.

Table 2 shows the results of the Spearman's correlation between Z2 (under each condition; PVR:  $\geq -500$  HU,  $\geq -550$  HU,  $\geq -600$  HU,  $\geq -650$  HU, and  $\geq -700$  HU, CT score:  $\geq -500$  HU, and  $\geq -600$  HU) and the two radiologists for PVR and the CT scores in the 10 participants without comorbidities, respectively. While the accuracy between the two radiologists and Z2 for PVR was equally high at  $\geq -500$  HU to  $\geq -600$  HU, the accuracy for CT scores was higher at  $\geq -600$  HU than at  $\geq -500$  HU. Based on these results, the Z2 measurement condition for COVID-19 pneumonia that achieved the best accuracy with the gross measurement was determined to be  $\geq -600$  HU.

**Table 2. Results of the Spearman's test of PVR and CT score by two radiologists and Z2 of five/two conditions in the 10 selected patients**

		Reader	$\geq -500$	$\geq -550$	$\geq -600$	$\geq -650$	$\geq -700$
		B	HU	HU	HU	HU	HU
Reader A	PVR	0.879	0.976	0.976	0.976	0.964	0.818
	CT score	0.976	0.639		0.651		
Reader B	PVR		0.842	0.842	0.842	0.83	0.661
	CT score		0.584		0.696		

PVR: pneumonia volume ratio, CT: computed tomography,

Reader A: M.S., Reader B: Y.F.

Figs 4 and 5 show the ROC curves and boxplots corresponding to the classification of disease severity by PVR and CT score using Z2 ( $\geq -600$  HU), CRP, and LDH. The areas under the curve (AUCs) were 0.881, 0.77, 0.788, and 0.842, respectively.

**Fig 5. ROC curves for PVR, CT score, CRP, and LDH.** ROC curve for **a.** PVR using Z2 ( $\geq -600$  HU) and **b.** CT scores using Z2 ( $\geq -600$  HU), **c.** CRP, and **d.** LDH. ROC, receiver operating characteristic; PVR, pneumonia volume ratio; Z2, Ziostation2; CT, computed tomography; CRP, C-reactive protein; LDH, lactate dehydrogenase; SD, standard deviation

**Fig 6. Boxplots of PVR, CT score, and CRP.** Boxplots for **a.** PVR using Z2 ( $\geq -600$  HU), **b.** CT scores using Z2 ( $\geq -600$  HU), **c.** CRP, and **d.** LDH. 1: mild group, 2: severe group. Error bars indicate outliers. PVR, pneumonia volume ratio; CT, computed tomography; Z2, Ziostation2; CRP, C-reactive protein; LDH, lactate dehydrogenase

The Youden index values for PVR and CT scores at  $\geq -600$  HU by Z2, CRP, and LDH were 18.69, 7.5, 5.26, and 306.5, respectively. The sensitivities for PVR and CT scores at  $\geq -600$  HU by Z2 were 66.7% and 40%, respectively. The specificities for PVR and CT scores at  $\geq -600$  HU by Z2 were 94.7% and 74%, respectively. The p-value for PVR at  $\geq -600$  HU by Z2 was  $p < 0.001$ , and that for CT scores at  $\geq -600$  HU by Z2 was  $p = 0.002$  (Table 3). The bivariable logistic regression of PVR ( $\geq -600$  HU) according to age, sex, date from onset to CT, and comorbidities showed no significant effects, except for comorbidities (Table 4). The sensitivity and specificity were 66.7% and 89.5% when the PVR threshold was 18, and 60% and 97.4% when the PVR threshold was 20, respectively.

**Table 3. Cut-off values for pneumonia volume ratio and blood test to differentiate mild and severe groups**

	Youden index	AUC	Sensitivity	Specificity	Lower 95% CI	Upper 95% CI	p-value
PVR ( $\geq -600$ HU)	18.69	0.881	66.7	94.7	0.781	0.981	< 0.001
CT score ( $\geq -600$ HU)	7.5	0.77	40	74	0.629	0.911	0.002
CRP	5.26	0.788	86.7	68.4	0.664	0.912	< 0.001
LDH	306.5	0.842	86.7	68.4	0.729	0.956	< 0.001

AUC: area under the curve, PVR: pneumonia volume ratio, CT: computed tomography, CRP: C-reactive protein, LDH: lactate dehydrogenase, CI: confidence interval

**Table 4. Bivariable logistic regression of PVR ( $\geq -600$  HU) according to age, sex, number of days from onset to CT, and comorbidities**

Predictor	OR (95% CI)	p-value
PVR ( $\geq -600$ HU)	1.131 (1.048–1.221)	0.002
Age	1.031 (0.979–1.086)	0.246
PVR ( $\geq -600$ HU)	1.124 (1.049–1.206)	0.001
Sex	0.000 (0.146–1530.796)	0.252

---

PVR ( $\geq -600$ HU)	1.126 (1.044–1.214)	0.002
Number of days from onset to CT	1.058 (0.837–1.339)	0.637
PVR ( $\geq -600$ HU)	1.137 (1.045–1.237)	0.003
Comorbidities (any)	9.795 (1.432–67.002)	0.02

---

PVR, pneumonia volume ratio; OR, odds ratio; CT, computed tomography; CI, confidence interval

The evaluation of PVR and CT scores in patients affected by COVID-19-associated pneumonia by Z2 was highly consistent with the visual-evaluation results under the condition of  $\geq -600$  HU. The AUC and Youden index of the ROC curve by Z2 ( $\geq -600$  HU) were 0.881 and 18.69 for PVR, and 0.77 and 7.5 for the CT score, respectively, indicating that they are useful for clinical severity classification.

## Discussion

The chest CT plays a major role in COVID-19 treatment, including severity judgment and prognostic prediction. In clinical practice and in previous studies, the spatial progression of pneumonia on CT has been evaluated with naked eye, and the accuracy and homogeneity have not been ensured.

In this study, we examined the usefulness of determining the severity of COVID-19-associated pneumonia using Z2, an image analysis software widely available in

Japan. This methodology can be easily deployed at facilities that have Z2 and thus has high clinical utility.

Several reports evaluated the percentage of lesion area of COVID-19-associated pneumonia in each lobe of the lung visually and scored them to determine the disease severity [6-10]. Yang et al. [6] visually classified the percentage of lesion area in each segment as 0%, <50%, and >50%. Li et al. [7] reported that the percentage of lesion area in each lobe was visually classified as 0%, 0–25%, 25–50%, 50–75%, and 75–100%, and scored on a scale of 0–20. The authors found that the optimal threshold for the severe group was 7.5. Francone et al. [9] used a similar classification, with a mortality risk cut-off of 18. Li et al. [8] also reported scores of 0:0%, 1:<5%, 2:5–25%, 3:25–50%, 4:50–75%, and 5:>75% or higher, with a cut-off score of 7, a sensitivity of 80%, and a specificity of 82.8% for the severely ill group. The cut-off value for clinical severity classification by CT score varies depending on the method and on how the severity is classified.

The CT scores based on visual evaluations that do not require special software or techniques are widely used in clinical settings. This type of evaluation is subjective; however, it has been reported that the inter-evaluator difference is small, and the results of this study are in agreement. However, the score measurement for each lobe in 25–50% increments is troublesome and imposes a burden on the emergency unit staff. Inoue et al. [11] reported that three visual CT score evaluations required 25.7-41.7 s, 27.7-39.5 s, and 48.9-80.0 s, respectively. Novel methods for the quantitative and automated measurement of the spatial progression of COVID-19-associated pneumonia have been reported since the early days of the pandemic [12-21].

Using the commercially available image analysis software, Timaran-Montenegro et al. [12] automatically classified –700 to –1000 HU as normal lung, and –500 to 20 HU as pneumonia regions, and compared the survival vs non-survival groups. The percentage of normal lung

was a significant independent factor according to a multinomial logistic analysis. Colombi et al. [13] defined the region of -950 to -700 HU as well as aerated lungs and reported that the measurement by commercially available software and visual measurement were very similar and useful for severity evaluation. In the 10 cases selected in our study, the correlation between the automated measurement by Z2 under the condition of  $\geq -600$  HU and the macroscopic measurement was high: very high for PVR (correlation coefficient 0.842-0.976) and moderate for the CT score (correlation coefficient 0.651-0.696). As there were no previous reports of using Z2 as a tool to evaluate diseases such as pneumonia with increased lung concentration, the concentration range for pneumonia was determined to be  $\geq -600$  HU in this study, based on the high degree of consistency in terms of visual PVR and CT score.

The range of normal lung, GGO, and consolidation reported in each study using software varied as follows: between: -1000 to -600 HU for normal lung, -750 to -100 HU for GGO, and -399 to -69 HU for consolidation [10-15]. Many previous studies set the lower limit of the GGO range at -800 to -700 HU; however, -600 HU was selected as the lower limit in this study due to the high degree of agreement with the visual findings. This was probably because it is difficult to recognize a faint increase in concentration based on visual evaluation compared to the software-assisted evaluation. It is an advantage of the software-assisted evaluation that it can detect faint concentrations; however, considering that the CT evaluation of COVID-19-associated pneumonia is generally based on visual evaluation, the detection of faint concentrations that are not measurable by visual evaluation leads to clinical discrepancies.

Grassi et al. [14] reported that the percentage of normal lung, emphysema, and consolidation measured by three different software tools were inconsistent. Granata et al. [15] compared the results obtained from two different software tools and reported that the correlation between



them was not high enough. The algorithms in which each software is based are different, and therefore comparisons cannot be made under uniform conditions. Z2 is a software tool owned by more than 300 facilities in Japan. Therefore, an assessment method based on the use of Z2 may be immediately available at these facilities and have a high clinical significance. In addition, the introduction of new technologies is time-consuming and expensive.

Okuma et al. [17] reported that the CT score and the percentage of opacity (PVR in this study) obtained using commercially available AI-based software showed a similar AUC; however, in this study the AUC corresponding to PVR and the CT score estimated by Z2 under  $\geq -600$  HU was higher in the case of PVR. Theoretically, the CT scoring method can differ by up to 24% in one lobe at the same point, making it less accurate than PVR. When automated measurement of the same standard becomes widespread, the evaluation by PVR is likely to replace CT scores.

Recently, there have been many reports on the diagnosis and severity assessment of COVID-19-associated pneumonia using AI [16-20]. In a study on COVID-19-associated pneumonia using an AI-based software developed by Ziosoft, the company that developed Z2, Aoki et al. [20] measured the CT lesion extent separately for normal lung, GGO, reticulation, and consolidation. In this study, the pneumonia area was evaluated by combining GGO and consolidation; however, more accurate qualitative and quantitative evaluation will be possible if AI-based software is adopted for this purpose in the future.

In this study, Z2 sometimes misidentified subpleural consolidation as extrapulmonary, requiring manual correction. Inoue et al. [11] reported the measurement errors with the use of U-NET due to the inclusion of atelectasis, fibrosis, and air trapping in the density mask. When a software tool is used, the measurement is carried out automatically; however, the error checking may still need to be performed by human staff.

In this study, we showed the optimal conditions for measuring the PVR and CT score in cases of COVID-19-associated pneumonia using Z2, a widely used image analysis software in Japan, and provided a guideline for clinical severity evaluation based on it. Therefore, defining a Z2-based assessment method has a high clinical significance, and replacing visual evaluation with existing image analysis software represents a way to quickly reduce the burden on clinicians at each facility.

Binomial logistic regression analysis showed no significant effects of age, sex, or time from onset to CT on PVR.

In terms of CT findings, consolidation was significantly higher among the severe group, in agreement with previous reports [9, 19-21]. Several laboratory tests have been reported to be indicators of COVID-19 infection. In our study, both CRP and LDH were significant items, again in agreement with previous reports [22, 23].

The major limitation of this study was the small number of participants at a single facility. The other limitations were that the manual correction of the subpleural consolidation in the Z2 measurement was performed by a single radiologist and the significance of inter-operator differences was not evaluated. Moreover, PVR assumed the area of  $\geq -600$  HU to be a surrogate value for COVID-19 pneumonia, but no histological confirmation was available. The PVR measurements were uniformly performed regardless of the background lesions affecting emphysema, fibrosis, or atelectasis.

In conclusion, we determined the optimal conditions that best approximates visual evaluation for assessing COVID-19-associated pneumonia using Z2, one of the most popular image analysis software tools in Japan and demonstrated that the AUC of PVR was higher than that of CT score in the assessment of clinical severity. The introduction of new technologies is time-consuming and expensive; this method has high clinical utility and can be adopted immediately in any facility where Z2 is available for use.

354

## 355 **Acknowledgments**

356 We would like to thank Dr. Noriko Hida and Dr. Eisuke Inoue for their guidance on the  
 357 statistical analysis, and Ms. Hokazono and Editage ([www.editage.com](http://www.editage.com)) for English language  
 358 editing. We also appreciate the support from our proofreaders and editors. In addition, we are  
 359 grateful to the clinicians at Fujisawa City Hospital for their insightful advice.

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

## 376 **References**

- 377 1. Hui DS, Azhar EI, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing  
378 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019  
379 novel coronavirus outbreak in Wuhan, China. *Int J Infect Dis.* 2020;91: 264-266. doi:  
380 10.1016/j.ijid.2020.01.009.
- 381 2. Furuse Y, Ko YK, Saito M, Shobugawa Y, Jindai K, Saito T, et al. Epidemiology of  
382 COVID-19 outbreak in Japan, from January-March 2020. *Jpn J Infect Dis.* 2020;73:  
383 391-393. doi: [10.7883/yoken.JJID.2020.271](https://doi.org/10.7883/yoken.JJID.2020.271).
- 384 3. Japanese Ministry of Health, Labour and Welfare. Regarding the response after the  
385 transition to Category 5 infectious diseases of the new coronavirus infectious disease;  
386 2023. Available from: <https://www.mhlw.go.jp/stf/corona5rui.html>.
- 387 4. Japanese Ministry of Health, Labour and Welfare. COVID-19 in Japan. Available from:  
388 <https://covid19.mhlw.go.jp/extensions/public/index.html> (2022).
- 389 5. Matsunaga N, Hayakawa K, Terada M, Ohtsu H, Asai Y, Tsuzuki S, et al. Clinical  
390 epidemiology of hospitalized patients with coronavirus disease 2019 (COVID-19) in  
391 Japan: report of the COVID-19 Registry Japan. *Clin Infect Dis.* 2021;73: e3677-e3689.  
392 doi: [10.1093/cid/ciaa1470](https://doi.org/10.1093/cid/ciaa1470).
- 393 6. Yang R, Li X, Liu H, Zhen Y, Zhang X, Xiong Q, et al. Chest CT severity score: an  
394 imaging tool for assessing severe COVID-19. *Radiol Cardiothorac Imaging.* 2020;2:  
395 e200047. doi: [10.1148/ryct.2020200047](https://doi.org/10.1148/ryct.2020200047).


7. Li K, Fang Y, Li W, Pan C, Qin P, Zhong Y, et al. CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19). *Eur Radiol.* 2020;30: 4407-4416. doi: [10.1007/s00330-020-06817-6](https://doi.org/10.1007/s00330-020-06817-6).
8. Li K, Wu J, Wu F, Guo D, Chen L, Fang Z, et al. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia. *Invest Radiol.* 2020;55: 327-331. doi: [10.1097/RLI.0000000000000672](https://doi.org/10.1097/RLI.0000000000000672).
9. Francone M, Iafrate F, Masci GM, Coco S, Cilia F, Manganaro L, et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. *Eur Radiol.* 2020;30: 6808-6817. doi: [10.1007/s00330-020-07033-y](https://doi.org/10.1007/s00330-020-07033-y).
10. Liang T, Liu Z, Wu CC, Jin C, Zhao H, Wang Y, et al. Evolution of CT findings in patients with mild COVID-19 pneumonia. *Eur Radiol.* 2020;30: 4865-4873. doi: [10.1007/s00330-020-06823-8](https://doi.org/10.1007/s00330-020-06823-8).
11. Inoue A, Takahashi H, Ibe T, Ishii H, Kurata Y, Ishizuka Y, et al. Comparison of semiquantitative chest CT scoring systems to estimate severity in coronavirus disease 2019 (COVID-19) pneumonia. *Eur Radiol.* 2022;32: 3513-3524. doi: [10.1007/s00330-021-08435-2](https://doi.org/10.1007/s00330-021-08435-2).
12. Timaran-Montenegro DE, Torres-Ramírez CA, Morales-Jaramillo LM, Mateo-Camacho YS, Tapia-Rangel EA, Fuentes-Badillo KD, et al. Computed tomography-based lung residual volume and mortality of patients with coronavirus disease-19 (COVID-19). *J Thorac Imaging.* 2021;36: 65-72. doi: [10.1097/RTI.0000000000000572](https://doi.org/10.1097/RTI.0000000000000572).
13. Colombi D, Bodini FC, Petrini M, Maffi G, Morelli N, Milanese G, et al. Well-aerated lung on admitting chest CT to predict adverse outcome in COVID-19 pneumonia. *Radiology.* 2020;296: E86-E96. doi: [10.1148/radiol.2020201433](https://doi.org/10.1148/radiol.2020201433).
14. Grassi R, Cappabianca S, Urraro F, Feragalli B, Montanelli A, Patelli G, et al. Chest CT computerized aided quantification of pneumonia lesions in COVID-19 infection: A

- comparison among three commercial software. Int J Environ Res Public Health. 2020;17: 6914. doi: [10.3390/ijerph17186914](https://doi.org/10.3390/ijerph17186914).
15. Granata V, Ianniello S, Fusco R, Urraro F, Pupo D, Magliocchetti S, et al. Quantitative analysis of residual COVID-19 lung CT features: consistency among two commercial software. J Pers Med. 2021;11: 1103. doi: [10.3390/jpm11111103](https://doi.org/10.3390/jpm11111103).
16. Kauczor HU, Heitmann K, Heussel CP, Marwede D, Uthmann T, Thelen M. Automatic detection and quantification of ground-glass opacities on high-resolution CT using multiple neural networks: comparison with a density mask. AJR Am J Roentgenol. 2000;175: 1329-1334. doi: [10.2214/ajr.175.5.1751329](https://doi.org/10.2214/ajr.175.5.1751329).
17. Okuma T, Hamamoto S, Maebayashi T, Taniguchi A, Hirakawa K, Matsushita S, et al. Quantitative evaluation of COVID-19 pneumonia severity by CT pneumonia analysis algorithm using deep learning technology and blood test results. Jpn J Radiol. 2021;39: 956-965. doi: [10.1007/s11604-021-01134-4](https://doi.org/10.1007/s11604-021-01134-4).
18. Durhan G, Ardalı Düzgün S, Başaran Demirkazık F, Irmak İ, İdilman İ, Gülsün Akpınar M, et al. Visual and software-based quantitative chest CT assessment of COVID-19: correlation with clinical findings. Diagn Interv Radiol. 2020;26: 557-564. doi: [10.5152/dir.2020.20407](https://doi.org/10.5152/dir.2020.20407).
19. Huang L, Han R, Ai T, Yu P, Kang H, Tao Q, et al. Serial quantitative chest CT assessment of COVID-19: A deep learning approach. Radiol Cardiothorac Imaging. 2020;2: e200075. doi: [10.1148/ryct.2020200075](https://doi.org/10.1148/ryct.2020200075).
20. Aoki R, Iwasawa T, Hagiwara E, Komatsu S, Utsunomiya D, Ogura T. Pulmonary vascular enlargement and lesion extent on computed tomography are correlated with COVID-19 disease severity. Jpn J Radiol. 2021;39: 451-458. doi: [10.1007/s11604-020-01085-2](https://doi.org/10.1007/s11604-020-01085-2).

- 445 21. Li Z, Zhong Z, Li Y, Zhang T, Gao L, Jin D, et al. From community-acquired pneumonia  
446 to COVID-19: a deep learning-based method for quantitative analysis of COVID-19 on  
447 thick-section CT scans. Eur Radiol. 2020;30: 6828-6837. doi:  
448 [10.1007/s00330-020-07042-x](https://doi.org/10.1007/s00330-020-07042-x).
- 449 22. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81  
450 patients with COVID-19 pneumonia in Wuhan, China: a descriptive  
451 study. Lancet Infect Dis. 2020;20: 425-434. doi: [10.1016/S1473-3099\(20\)30086-4](https://doi.org/10.1016/S1473-3099(20)30086-4).
- 452 23. Kurashima K, Kagiya N, Ishiguro T, Kasuga K, Morimoto Y, Ozawa R, et  
453 al. Predictors of severe COVID-19 pneumonia. Kansenshogaku Zasshi. 2020;94:  
454 483-489. doi: [10.11150/kansenshogakuzasshi.94.483](https://doi.org/10.11150/kansenshogakuzasshi.94.483).



Fig. 1



	lung	LAV	LAV %	nLAV	nLAV%
total	4158.82cc	3822.92cc	91.91%	335.90cc	8.08%
left lung	1945.06cc	1757.83cc	90.37%	187.23cc	9.63%
LU	128.95cc	1012.16cc	89.68%	116.19cc	10.32%
LL	816.11cc	745.37cc	91.33%	70.74cc	8.67%
right lung	2213.76cc	2065.09cc	93.26%	148.66cc	6.72%
RU	525.98cc	487.86cc	92.75%	38.13cc	7.25%
RM	680.66cc	531.37cc	90.57%	29.29cc	4.43%
RL	1027.12cc	945.87cc	92.08%	81.25cc	7.91%

Histogram






Fig. 2

: -884.00  
: 899.00  
: 184.83

area : 439.65 mm2  
mean : -657.44  
min : -906.00  
max : -119.00  
SD : 148.78

: 598.28  
: -579.6  
: -871.0  
: 29.00  
: 168.63

: 14873.18 mm2  
: -554.32  
: -945.00  
: 899.00  
: 229.06

: 12730.09 mm2  
: -766.13  
: -940.00  
: 638.00  
: 157.41





Fig. 3



**Fig 4.**










Fig. 5




**Fig. 6**

**a.**




**CT score**

**b.**



**c.**



**CRP**

**d.**

